Vertex PharmaceuticalsWBO:VRTX +2.51%90 EBITDA Margin % is 40.00% as of Mar. 2026, which is 5% above its 10-year median of 38.00. GuruFocus rates WBO:VRTX with a GF Score™ of 90/100 and a GF Value™ of €439.78 (Fairly Valued). The stock has 4 warning signs investors should review. Among 945 Biotechnology companies, Vertex Pharmaceuticals ranks better than 92.8% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Vertex Pharmaceuticals EBITDA Margin % Related Terms
Vertex Pharmaceuticals EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Vertex Pharmaceuticals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:VRTX vs REGN, ALNY, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, Vertex Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vertex Pharmaceuticals EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vertex Pharmaceuticals (WBO:VRTX) has a EBITDA Margin % of 40.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vertex Pharmaceuticals and its competitors. This is near median its historical median of 38.00. Over the past decade, Vertex Pharmaceuticals' EBITDA Margin % has ranged from 4.41 to 52.93. According to the industry distribution chart, Vertex Pharmaceuticals ranks #68 out of 945 companies in the Biotechnology industry, placing it in the top 7.2%.
Is Vertex Pharmaceuticals' EBITDA Margin % too high?
Vertex Pharmaceuticals' current EBITDA Margin % of 40.00% is near median its 10-year median of 38.00. Over the past 10 years, this metric has ranged from a low of 4.41 to a high of 52.93. Based on the distribution chart, Vertex Pharmaceuticals ranks #68 out of 945 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vertex Pharmaceuticals has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' EBITDA Margin % compare to REGN and ALNY?
According to the Biotechnology industry distribution chart, Vertex Pharmaceuticals ranks #68 out of 945 companies for EBITDA Margin %. This places Vertex Pharmaceuticals in the top 7% of its industry — outperforming the majority of peers. Historically, Vertex Pharmaceuticals' own EBITDA Margin % has ranged from 4.41 to 52.93 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vertex Pharmaceuticals and its competitors. Vertex Pharmaceuticals's current EBITDA Margin % is 40.00%, which is near median its own 10-year median of 38.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (WBO:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is €439.78, compared to a current price of €410.10 — trading 6.7% below its estimated fair value. The current EBITDA Margin % is 40.00%, which is near median its 10-year median of 38.00. Vertex Pharmaceuticals' overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Vertex Pharmaceuticals (WBO:VRTX), the current EBITDA Margin % is 40.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vertex Pharmaceuticals (WBO:VRTX) Overvalued in 2026?
Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued.
The current stock price of €410.10 is trading 6.7% below its estimated GF Value™ of €439.78.
GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.
Key valuation signals for WBO:VRTX:
EBITDA Margin %: 40.00% (near median its 10-year median of 38.00)
GF Value™: €439.78 vs. price of €410.10 (6.7% below fair value)
No single metric tells the full story. See the WBO:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
90GF Score
Get the complete analysis for WBO:VRTX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:VRTX has been successfully added to your 
